Remdesivir bei Patienten mit COVID-19

Hallek, Michael; Nitschmann, S.

doi:10.1007/s00108-020-00836-7

Cited by 5 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Für die Behandlung von Patienten mit „coronavirus disease 2019“ (COVID-19) wurden unterschiedliche medikamentöse Therapieansätze verfolgt: Kortikoide, Antikoagulanzien, Interleukin-6-Rezeptor-Antagonisten (IL-6-RA), monoklonale Antikörper gegen das Spike-Protein, antiinflammatorische und antivirale Medikamente. Letztere sind in Form von Remdesivir (Veklury, seit 07/2020; [ 1 , 2 ]), Molnupiravir (Lagevrio, seit 01/2022) und Nirmatrelvir + Ritonavir (Paxlovid, seit 1/2022) in Deutschland verfügbar. Eine Zulassung in Europa besteht derzeit nur für Remdesivir und Paxlovid.…”

Section: Originalliteraturunclassified

Antivirale Therapie bei Patienten mit COVID-19

Hallek

Nitschmann

2022

Innere Medizin

View full text Add to dashboard Cite

Section: Originalliteraturunclassified

Antivirale Therapie bei Patienten mit COVID-19

Hallek

Nitschmann

2022

Innere Medizin

View full text Add to dashboard Cite

“…There is insufficient evidence presently to confidently exclude RDV as a treatment option in COVID-19 patients. What is required from future randomized trials is to determine the correct dose and timing of the drug, and which routes of administration and combination therapies are most effective (44) bearing in mind that hepatic and renal adverse events have been reported (45,46) and must be considered in risk-benefit decisions.…”

Section: Antiviralsmentioning

confidence: 99%

The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time

et al. 2021

View full text Add to dashboard Cite

The pandemic caused by SARS-CoV-2 has infected more than 94 million people worldwide (as of 17 January 2020). Severe disease is believed to be secondary to the cytokine release syndrome (CRS or “cytokine storm”) which causes local tissue damage as well as multi-organ dysfunction and thrombotic complications. Due to the high mortality rates in patients receiving invasive ventilation, practice has changed from “early-intubation” for acute respiratory distress syndrome (ARDS) to a trial of non-invasive ventilation (NIV) or high flow nasal cannula (HFNC) oxygen. Reports indicating the benefit of NIV and HFNC have been encouraging and have led to more than 20,000 such devices being manufactured and ready for roll-out in South Africa (SA) as of July 2020. The need to identify drugs with clear clinical benefits has led to an array of clinical trials, most of which are repurposing drugs for COVID-19. The treatment landscape reflects the need to target both the virus and its effects such as the CRS and thrombotic complications. Conflicting results have the potential to confuse the implementation of coordinated treatment strategies and guidelines. The purpose of this review is to address pertinent areas in the current literature on the available medical treatment options for COVID-19. Remdesivir, tocilizumab, and dexamethasone are some of the treatment options that have shown the most promise, but further randomized trials are required to particularly address timing and dosages to confidently create standardized protocols. For the SA population, two healthcare sectors exist. In the private sector, patients with medical insurance may have greater access to a wider range of treatment options than those in the public sector. The latter serves >80% of the population, and resource constraints require the identification of drugs with the most cost-effective use for the greatest number of affected patients.

show abstract

“…Seit der ersten beschriebenen Infektion mit dem „severe acute respiratory syndrome coronavirus 2“ (SARS-CoV-2) im Dezember 2019 hat sich die „coronavirus disease 2019“ (COVID-19) zu einer Pandemie entwickelt, deren Symptomatik von einem asymptomatischen Verlauf bis hin zu akutem Lungen- und Multiorganversagen sowie Tod reicht. Unterschiedliche medikamentöse Therapieansätze wurden verfolgt, so etwa die Therapie mit Remdesivir [ 1 ] oder Dexamethason, eine spezifische Therapie gibt es bisher jedoch nicht. In präklinischen Studien konnte eine Reduktion der Viruslast und damit ein leichterer Erkrankungsverlauf durch die Gabe spezifischer Antikörper erreicht werden.…”

Section: Originalliteraturunclassified